By Finance Pulse in Transformative —

H.C. Wainwright Upgrades Aclaris Therapeutics to Buy

H.C. Wainwright upgrades Aclaris Therapeutics (ACRS) to Buy, setting a $20 price target following an exclusive license deal with Biosion. Explore investment opportunities in biotech growth.

A modern, sleek image featuring the stock market graph rising with a subtle biotech theme, symbolizi
H.C. Wainwright Upgrades Aclaris Therapeutics to Buy

H.C. Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy due to an exclusive license agreement with Biosion, with a $20 price target.

Source